Rebeccamycin Analog in Treating Patients With Advanced Kidney Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00005027|
Recruitment Status : Completed
First Posted : August 8, 2003
Last Update Posted : April 5, 2013
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of rebeccamycin analog in treating patients who have advanced kidney cancer.
|Condition or disease||Intervention/treatment||Phase|
|Kidney Cancer||Drug: becatecarin||Phase 2|
- Determine the response rate of patients with advanced renal cell carcinoma when treated with rebeccamycin analogue.
- Assess the quantitative and qualitative toxicities associated with this drug in this patient population.
OUTLINE: Patients receive rebeccamycin analogue IV over 30-60 minutes daily for 5 days. Treatment continues every 21 days in the absence of disease progression or unacceptable toxicity.
PROJECTED ACCRUAL: A total of 23-44 patients will be accrued for this study within 9-18 months.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||A Phase II Study of Rebeccamycin Analog in Renal Cell Cancer|
|Study Start Date :||June 2000|
|Actual Primary Completion Date :||March 2005|
|Actual Study Completion Date :||March 2005|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00005027
|United States, Michigan|
|Barbara Ann Karmanos Cancer Institute|
|Detroit, Michigan, United States, 48201-1379|
|Study Chair:||Ulka N. Vaishampayan, MD||Barbara Ann Karmanos Cancer Institute|